| Literature DB >> 29322778 |
Alicia J Angelbello1, Jonathan L Chen1, Jessica L Childs-Disney1, Peiyuan Zhang1, Zi-Fu Wang1, Matthew D Disney1.
Abstract
Rapid progress in genome sequencing technology has put us firmly into a postgenomic era. A key challenge in biomedical research is harnessing genome sequence to fulfill the promise of personalized medicine. This Review describes how genome sequencing has enabled the identification of disease-causing biomolecules and how these data have been converted into chemical probes of function, preclinical lead modalities, and ultimately U.S. Food and Drug Administration (FDA)-approved drugs. In particular, we focus on the use of oligonucleotide-based modalities to target disease-causing RNAs; small molecules that target DNA, RNA, or protein; the rational repurposing of known therapeutic modalities; and the advantages of pharmacogenetics. Lastly, we discuss the remaining challenges and opportunities in the direct utilization of genome sequence to enable design of medicines.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29322778 PMCID: PMC5989578 DOI: 10.1021/acs.chemrev.7b00504
Source DB: PubMed Journal: Chem Rev ISSN: 0009-2665 Impact factor: 60.622